CCHT(SZ:000661) Zheng Quan Shi Bao Wang·2025-10-13 10:40Core Viewpoint - Changchun High-tech (000661) announced that its subsidiary, Changchun Baike Biotechnology Co., Ltd. (referred to as "Baike Biotechnology"), has received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its trivalent influenza virus split vaccine (BK-01 adjuvant), allowing the company to conduct clinical trials for the vaccine aimed at preventing influenza caused by related strains of the virus [1] Group 1 - The approval from the National Medical Products Administration is a significant milestone for Baike Biotechnology in the development of its influenza vaccine [1] - The clinical trials will focus on the efficacy of the trivalent influenza virus split vaccine in preventing influenza outbreaks [1]